{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:47:32Z","timestamp":1787168852094,"version":"build-2736575974"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"7","funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation for the Finnish Cancer Institute"},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["289059"],"award-info":[{"award-number":["289059"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["319243"],"award-info":[{"award-number":["319243"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["317680"],"award-info":[{"award-number":["317680"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["320131"],"award-info":[{"award-number":["320131"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["351165"],"award-info":[{"award-number":["351165"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["351196"],"award-info":[{"award-number":["351196"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["344697"],"award-info":[{"award-number":["344697"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007798","name":"University of Helsinki Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007798","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009067","name":"K. Albin Johanssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007634","name":"Ida Montinin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["716063"],"award-info":[{"award-number":["716063"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101125261"],"award-info":[{"award-number":["101125261"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["101130349"],"award-info":[{"award-number":["101130349"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Whereas FMS-like tyrosine kinase-3 (FLT3) inhibitors have significantly improved the treatment of aggressive FLT3-mutated acute myeloid leukemia (AML), the emergence of resistance remains as a major challenge. In this study, we applied our recently developed single-cell lineage-tracing method ReSisTrace to identify cells that are intrinsically resistant or sensitive to the FLT3 inhibitors midostaurin and quizartinib in AML with FLT3-ITD mutations. Comparison of the gene expression profiles of these cells revealed transcriptional resistance signatures, including upregulation of GSPT1. Depletion of GSPT1 with CRISPR-Cas9\u2013mediated knockout resulted in increased sensitivity of AML cells to quizartinib treatment. Furthermore, targeting GSPT1 with the small molecule CC-90009 exhibited strong synergistic effects when combined with FLT3 inhibitors in the FLT3-ITD cell lines and primary AML patient samples. In addition, in an FLT3-ITD\u2013positive AML patient-derived xenograft mouse model, the CC-90009 and quizartinib combination showed significantly higher antitumor efficacy and prolonged overall survival compared with either treatment alone. Furthermore, compounds that induced transcriptomic changes opposite to the resistance signatures prompted cells to acquire FLT3 inhibitor\u2013sensitive states. Vistusertib (mTOR inhibitor), linsitinib (IGF1R and INSR inhibitor), and meisoindigo (IGF1R and SRC family kinase inhibitor), all inhibiting pathways parallel to or downstream of oncogenic FLT3 signaling, were predicted and validated to sensitize FLT3-mutated cell lines and primary cells to FLT3 inhibitors. Collectively, these findings demonstrate the ability of ReSisTrace to unveil preexisting transcriptional features of treatment vulnerability in hematologic cancers and elucidate strategies for enhancing FLT3 inhibitor treatment efficacy in FLT3-ITD\u2013mutated AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Single-cell lineage tracing with ReSisTrace reveals cellular states that prime treatment resistance and identifies approaches to sensitize FLT3-ITD\u2013positive acute myeloid leukemia to FLT3 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-3753","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:59:28Z","timestamp":1763751568000},"page":"1724-1738","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2238-3227","authenticated-orcid":false,"given":"Johanna","family":"Eriksson","sequence":"first","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0624-8077","authenticated-orcid":false,"given":"Shuyu","family":"Zheng","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-3815","authenticated-orcid":false,"given":"Mihaela","family":"Popa","sequence":"additional","affiliation":[{"name":"2Precision Oncology Research Group, University of Bergen, Bergen, Norway."},{"name":"3Kinn Therapeutics AS, Bergen, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-7309","authenticated-orcid":false,"given":"Jie","family":"Bao","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-5216","authenticated-orcid":false,"given":"Jun","family":"Dai","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-9740","authenticated-orcid":false,"given":"Wenyu","family":"Wang","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-4625","authenticated-orcid":false,"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[{"name":"2Precision Oncology Research Group, University of Bergen, Bergen, Norway."},{"name":"4Department of Clinical Science, University of Bergen, Bergen, Norway."},{"name":"5Department of Hematology, Haukeland University Hospital, Bergen, Norway."},{"name":"6Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway."},{"name":"7Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-3954","authenticated-orcid":false,"given":"Anna","family":"V\u00e4h\u00e4rautio","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."},{"name":"8Foundation for the Finnish Cancer Institute, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-7710","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"2026040203064697500_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"2026040203064697500_bib2","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"key":"2026040203064697500_bib3","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"2026040203064697500_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"2026040203064697500_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.thj.6200224","article-title":"Prognostic significance of FLT3 ITD and D835 mutations in AML patients","volume":"4","author":"Sheikhha","year":"2003","journal-title":"Hematol J"},{"key":"2026040203064697500_bib6","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"2026040203064697500_bib7","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026040203064697500_bib8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"key":"2026040203064697500_bib9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"2026040203064697500_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026040203064697500_bib11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"key":"2026040203064697500_bib12","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41467-019-10652-9","article-title":"Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia","volume":"10","author":"Bell","year":"2019","journal-title":"Nat Commun"},{"key":"2026040203064697500_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-21-0050","article-title":"Genetic and transcriptional contributions to relapse in normal karyotype acute myeloid leukemia","volume":"3","author":"Petti","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026040203064697500_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"2026040203064697500_bib15","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1158\/0008-5472.CAN-23-0144","article-title":"Expressed barcoding enables high-resolution tracking of the evolution of drug tolerance","volume":"83","author":"Cotton","year":"2023","journal-title":"Cancer Res"},{"key":"2026040203064697500_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13073-024-01327-2","article-title":"Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer","volume":"16","author":"Pellecchia","year":"2024","journal-title":"Genome Med"},{"key":"2026040203064697500_bib17","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat Commun"},{"key":"2026040203064697500_bib18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41467-024-45478-7","article-title":"Tracing back primed resistance in cancer via sister cells","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"2026040203064697500_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"2026040203064697500_bib20","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"2026040203064697500_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gr.209601.116","article-title":"UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy","volume":"27","author":"Smith","year":"2017","journal-title":"Genome Res"},{"key":"2026040203064697500_bib22","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026040203064697500_bib23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"2026040203064697500_bib24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026040203064697500_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"2026040203064697500_bib26","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.xcrm.2021.100492","article-title":"A community challenge for a pancancer drug mechanism of action inference from perturbational profile data","volume":"3","author":"Douglass","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026040203064697500_bib27","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1093\/nar\/gkz805","article-title":"Signatures of cell death and proliferation in perturbation transcriptomics data-from confounding factor to effective prediction","volume":"47","author":"Szalai","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026040203064697500_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","article-title":"PharmacoGx: an R package for analysis of large pharmacogenomic datasets","volume":"32","author":"Smirnov","year":"2016","journal-title":"Bioinformatics"},{"key":"2026040203064697500_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2026040203064697500_bib30","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1038\/s41467-022-31830-2","article-title":"Accurate determination of CRISPR-mediated gene fitness in transplantable tumours","volume":"13","author":"Eirew","year":"2022","journal-title":"Nat Commun"},{"key":"2026040203064697500_bib31","doi-asserted-by":"crossref","first-page":"103522","DOI":"10.1016\/j.xpro.2024.103522","article-title":"Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy","volume":"5","author":"Safont","year":"2024","journal-title":"STAR Protoc"},{"key":"2026040203064697500_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1947601910362446","article-title":"Wnt\/\u03b2-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3\u03b2 dependent manner","volume":"1","author":"Jiang","year":"2010","journal-title":"Genes Cancer"},{"key":"2026040203064697500_bib33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J Med Chem"},{"key":"2026040203064697500_bib34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/cb300687k","article-title":"A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes","volume":"8","author":"Jung","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2026040203064697500_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-021-00433-3","article-title":"OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia","volume":"11","author":"Eisfelder","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026040203064697500_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","article-title":"JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML","volume":"130","author":"Karjalainen","year":"2017","journal-title":"Blood"},{"key":"2026040203064697500_bib37","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways","volume":"109","author":"Piloto","year":"2007","journal-title":"Blood"},{"key":"2026040203064697500_bib38","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"2026040203064697500_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"2026040203064697500_bib40","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res"},{"key":"2026040203064697500_bib41","doi-asserted-by":"crossref","first-page":"e79940","DOI":"10.7554\/eLife.79940","article-title":"Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation","volume":"11","author":"Park","year":"2022","journal-title":"Elife"},{"key":"2026040203064697500_bib42","doi-asserted-by":"crossref","first-page":"100830","DOI":"10.1016\/j.jbior.2021.100830","article-title":"Synergistic cytotoxicity of dual PI3K\/mTOR and FLT3 inhibition in FLT3-ITD AML cells","volume":"82","author":"Darici","year":"2021","journal-title":"Adv Biol Regul"},{"key":"2026040203064697500_bib43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med Chem"},{"key":"2026040203064697500_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","article-title":"Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer","volume":"16","author":"Hopkins","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026040203064697500_bib45","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/molecules22091546","article-title":"Methylisoindigo and its bromo-derivatives are selective tyrosine kinase inhibitors, repressing cellular Stat3 activity, and target CD133+ cancer stem cells in PDAC","volume":"22","author":"Tegethoff","year":"2017","journal-title":"Molecules"},{"key":"2026040203064697500_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.leu.2404547","article-title":"Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD","volume":"21","author":"Okamoto","year":"2007","journal-title":"Leukemia"},{"key":"2026040203064697500_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/leu.2009.301","article-title":"FES kinases are required for oncogenic FLT3 signaling","volume":"24","author":"Voisset","year":"2010","journal-title":"Leukemia"},{"key":"2026040203064697500_bib48","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/1042819021000006295","article-title":"Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China","volume":"43","author":"Xiao","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2026040203064697500_bib49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3109\/10428191003672115","article-title":"Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia","volume":"51","author":"Lee","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2026040203064697500_bib50","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","article-title":"First-in-Human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1\/2 inhibitor AZD2014","volume":"21","author":"Basu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026040203064697500_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026040203064697500_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2141.2000.02357.x","article-title":"Meisoindigo for the treatment of chronic myelogenous leukaemia","volume":"111","author":"Xiao","year":"2000","journal-title":"Br J Haematol"},{"key":"2026040203064697500_bib53","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"key":"2026040203064697500_bib54","doi-asserted-by":"crossref","first-page":"47018","DOI":"10.18632\/oncotarget.10147","article-title":"Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2026040203064697500_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cancers17020211","article-title":"PROTAC-mediated GSPT1 degradation impairs the expression of fusion genes in acute myeloid leukemia","volume":"17","author":"Perzolli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026040203064697500_bib56","doi-asserted-by":"crossref","first-page":"e153514","DOI":"10.1172\/JCI153514","article-title":"Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells","volume":"132","author":"Sellar","year":"2022","journal-title":"J Clin Invest"},{"key":"2026040203064697500_bib57","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1128\/MCB.00035-07","article-title":"Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway","volume":"27","author":"Chauvin","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2026040203064697500_bib58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-3753\/3683599\/can-24-3753.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-3753\/3726235\/can-24-3753.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1724\/3753378\/can-24-3753.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1724\/3753378\/can-24-3753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:07:00Z","timestamp":1775113620000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/7\/1724\/775633\/Single-Cell-Lineage-Tracing-Uncovers-Resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-3753","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.31923806","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923803","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923779","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923791","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923770","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923788","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923800","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923767","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923797","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923764","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923776","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923773","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923785","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923782","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923794","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923761","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8398388","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}